Retrospective analysis of 264 multiple myeloma patients
- Authors:
- Chuanying Geng
- Nian Liu
- Guangzhong Yang
- Aijun Liu
- Yun Leng
- Huijuan Wang
- Lihong Li
- Yin Wu
- Yanchen Li
- Wenming Chen
View Affiliations
Affiliations: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China
- Published online on: November 9, 2012 https://doi.org/10.3892/ol.2012.1018
-
Pages:
707-713
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Multiple myeloma (MM) is the second most common hematological malignancy in China. However, there are only a small number of large cohort studies demonstrating the clinical features of newly diagnosed MM. In the present study, 264 newly diagnosed MM patients from the Beijing Chaoyang Hospital were retrospectively analyzed. The median patient age was 59 years (range, 28‑84) and the most common monoclonal protein (42%) was the IgG subtype. Of the 49 patients detected by FISH, 10.2, 2.0 and 12.2% demonstrated del(17p), t(14;16) and t(4;14), respectively. In total, 228 (86%) patients achieved either a complete response (CR), a very good partial response (VGPR) or a partial response (PR). The overall response rate (ORR) in non-autologous stem cell transplantation (non‑ASCT) patients was 83.0%, with 48 (18.2%), 7 (2.7%) and 121 (45.8%) patients achieving CR, VGPR and PR, respectively. ASCT patients achieved at least a PR prior to ASCT, and ASCT was not able to increase the ORR (P=0.55). Non‑ASCT patients who received bortezomib-based regimens demonstrated an improved ORR compared with those who received regimens that did not contain bortezomib (92.3% vs. 75.8%; P<0.05). With a median follow-up time of 20 months, the estimated median progression-free survival (PFS) and overall survival (OS) times were 27.6 and 61.0 months, respectively. The OS time of patients with high-risk cytogenetic abnormality, del(17p), t(14;16) and t(4;14), was shorter compared with that of other patients (30.2 months vs. not reached, P=0.029). Patients who achieved a CR/VGPR in the ASCT group demonstrated a greater OS time compared with non-ASCT patients (P=0.031). Relapsed patients who received bortezomib-based regimens did not demonstrate a longer survival time post-relapse compared with those who received non-bortezomib-based regimens (26.5 months vs. 10.5 months; P=0.271). The current study presented the clinical characteristics of MM patients who were initially treated at the Beijing Chaoyang Hospital. Bortezomib-based regimens and ASCT were able to improve the OS of MM patients.
View References
|
1.
|
Raab MS, Podar K, Breitkreutz I,
Richardson PG and Anderson KC: Multiple myeloma. Lancet.
374:324–339. 2009. View Article : Google Scholar
|
|
2.
|
Rajkumar SV: Multiple myeloma: 2011 update
on diagnosis, risk-stratification, and management. Am J Hematol.
86:57–65. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Kyle RA and Rajkumar SV: Multiple myeloma.
Blood. 111:2962–2972. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Kyle RA, Gertz MA, Witzig TE, et al:
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo
Clin Proc. 78:21–33. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Durie BG, Harousseau JL, Miguel JS, et al:
International uniform response criteria for multiple myeloma.
Leukemia. 20:1467–1473. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Becker N: Epidemiology of multiple
myeloma. Recent Results Cancer Res. 183:25–35. 2011. View Article : Google Scholar
|
|
7.
|
Tuscano JM: Multiple myeloma: epidemiology
and therapeutic options. Manag Care. 17:9–15. 2008.PubMed/NCBI
|
|
8.
|
Mileshkin L, Biagi JJ, Mitchell P, et al:
Multicenter phase 2 trial of thalidomide in relapsed/refractory
multiple myeloma: adverse prognostic impact of advanced age. Blood.
102:69–77. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Choi JH, Yoon JH and Yang SK: Clinical
value of new staging systems for multiple myeloma. Cancer Res
Treat. 39:171–174. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Greipp PR, San Miguel J, Durie BG, et al:
International staging system for multiple myeloma. J Clin OncoI.
23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Avet-Loiseau H, Attal M, Moreau P, et al:
Genetic abnormalities and survival in multiple myeloma: the
experience of the Intergroupe Francophone du Myélome. Blood.
109:3489–3495. 2007.PubMed/NCBI
|
|
12.
|
Gutiérrez NC, Castellanos MV, Martín ML,
et al: Prognostic and biological implications of genetic
abnormalities in multiple myeloma undergoing autologous stem cell
transplantation: t(4;14) is the most relevant adverse prognostic
factor, whereas RB deletion as a unique abnormality is not
associated with adverse prognosis. Leukemia. 21:143–150. 2007.
|
|
13.
|
Nadal E, Giné E, Bladé J, et al: High-dose
therapy/autologous stem cell transplantation in patients with
chemosensitive myeloma: predictors of complete remission. Bone
Marrow Transplant. 33:61–64. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Lahuerta JJ, Mateos MV, Martínez-López J,
et al: Influence of pre- and post-transplantation responses on
outcome of patients with multiple myeloma: sequential improvement
of response and achievement of complete response are associated
with longer survival. J Clin Oncol. 26:5775–5782. 2008. View Article : Google Scholar
|
|
15.
|
van de Velde HJ, Liu X, Chen G, et al:
Complete response correlates with long-term survival and
progression-free survival in high-dose therapy in multiple myeloma.
Haematologica. 92:1399–1406. 2007.PubMed/NCBI
|
|
16.
|
Delforge M: Bortezomib for previously
untreated multiple myeloma. Expert Opin Pharmacother. 12:2553–2564.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Terpos E, Roussou M and Dimopoulos MA:
Bortezomib in multiple myeloma. Expert Opin Drug Metab Toxicol.
4:639–654. 2008. View Article : Google Scholar
|
